BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Antitope Announces Research Cooperation with the University of North Carolina at Chapel Hill


8/4/2011 12:11:37 PM

Cambridge UK, 27th July 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research collaboration with the University of North Carolina at Chapel Hill, NC, USA (“UNC”) for the generation of monoclonal therapeutic antibodies for the treatment of cancer. During the collaboration, Antitope will apply its Composite Human AntibodyTM technology to generate fully-humanized antibodies that are devoid of T cell epitopes and have a reduced risk of clinical immunogenicity.

“We are delighted that UNC is working with Antitope to generate humanized antibodies with low immunogenic potential,” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, “Our collaboration has yet again demonstrated the success of our Composite Human AntibodyTM technology and we are excited about the prospect of working with UNC on developing therapeutic anti-cancer antibodies.”

“After discovering a novel angiogenesis factor and generating a monoclonal antibody that inhibits tumor growth in a pre-clinical model, we set out to find a company that had strong experience with humanization of monoclonal antibodies,” said Dr Nancy DeMore, Associate Professor of Surgery at the UNC School of Medicine and a member of the UNC Lineberger Comprehensive Cancer Center. “We consulted with other scientists, researched Antitope’s methods and determined that collaborating with them would be optimal.”

About Antitope Ltd.:

Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreenTM technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human AntibodyTM technology results in the generation of humanized antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.

About the University of North Carolina at Chapel Hill:

The University of North Carolina at Chapel Hill, the United States’ first public university, is a leader in American higher education and known around the world for innovative teaching, research and public service. Carolina offers bachelor's, master's, doctorate and professional degree programs through 14 schools and the College of Arts and Sciences. Every day, faculty, staff and students shape their teaching, research and public service priorities to meet North Carolina’s most pressing needs. UNC-Chapel Hill is implementing Innovate@Carolina, a plan to help Carolina become a world leader in launching university-born ideas for the good of society. (For information, refer to www.unc.edu.)

Contact Information:

Antitope Limited

Neil Butt PhD

Business Development

Tel: +44 1223 496190

Email: info@antitope.co.uk



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES